ImpediMed Limited (IPD:ASX) Annual Reports & Investor Relations Material

Overview

ImpediMed Limited is a medical software technology company that specializes in the development, manufacturing, and selling of bioimpedance spectroscopy (BIS) devices and software services. With a presence in Australia, North America, and globally, the company offers SOZO, a noninvasive BIS device for assessing lymphedema and monitoring fluid status in heart failure patients. Additionally, ImpediMed provides SFB7, a single-channel, tetrapolar BIS device that analyzes body composition in healthy individuals, and ImpediVET, a veterinary application for measuring fluid status and tissue composition. The company's clientele comprises hospitals and clinics worldwide. ImpediMed Limited was established in 1999 and is headquartered in Pinkenba, Australia.

Frequently Asked Questions

What is ImpediMed Limited's ticker?

ImpediMed Limited's ticker is IPD

What exchange is ImpediMed Limited traded on?

The company's shares trade on the ASX stock exchange

Where are ImpediMed Limited's headquarters?

They are based in Pinkenba, Australia

How many employees does ImpediMed Limited have?

There are 51-200 employees working at ImpediMed Limited

What is ImpediMed Limited's website?

It is https://www.impedimed.com/

What type of sector is ImpediMed Limited?

ImpediMed Limited is in the Healthcare sector

What type of industry is ImpediMed Limited?

ImpediMed Limited is in the Medical Appliances & Equipment industry

Who are ImpediMed Limited's peers and competitors?

The following five companies are ImpediMed Limited's industry peers:

- ViewRay

- Advanced Oncotherapy

- Quanterix

- Zynex

- NanoVibronix, Inc.